DETROIT--(BUSINESS WIRE)--Asterand plc (LSE: ATD), (“Asterand” or the “Company”), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, announces today that it has entered into a Global Framework Research Agreement with Lundbeck A/S, a leading international pharmaceutical company focused on the development of medications for central nervous system disorders. This agreement will allow scientists at Lundbeck’s global research locations to access Asterand's XpressBANKTM of human tissue and clinical data and the PhaseZERO® drug discovery services platform to advance development of treatments for psychiatric and neurological disorders. Financial terms were not disclosed.
